Format

Send to

Choose Destination
Alzheimers Dement. 2014 Jan;10(1):109-14. doi: 10.1016/j.jalz.2013.10.007.

Developing novel blood-based biomarkers for Alzheimer's disease.

Author information

1
Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: hsnyder@alz.org.
2
Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
3
Department of Medicine, Brigham and Women's Hospital, Inc., Boston, MA, USA.
4
Biomarker and Research Division, Nordic Biosciences, Copenhagen, Denmark.
5
NextGen Sciences Dx, Gainesville, FL, USA.
6
Institute of Psychiatry, Department of Medicine and Neurosciences, King's College, London, UK.
7
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
8
Internal Medicine Department, University of North Texas Health Sciences Center at Fort Worth, Fort Worth, TX, USA.
9
Araclon Biotech, Zaragoza, Spain.
10
Diagenic ASA, Oslo, Norway.
11
Bristol Myers Squibb, Co., Wallingford, CT, USA.
12
University of Southampton, Southampton, UK.
13
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
14
Proteome Sciences plc, London, UK.
15
C2N Diagnostics, St Louis, MO, USA.
16
Independent Science Writer, Philadelphia, PA, USA.
17
Alzheimer's Drug Discovery Foundation, New York, NY, USA.
18
School of Medicine, University of California-San Francisco, San Francisco, CA, USA; Department of Veterans Affairs Medical Center, San Francisco, CA, USA.

Abstract

Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

KEYWORDS:

Alzheimer's disease; Biomarker; Blood based biomarker; Diagnostics; Early detection; Early diagnosis

PMID:
24365657
PMCID:
PMC4769619
DOI:
10.1016/j.jalz.2013.10.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center